What is standard, first-line therapy for men with mHSPC today?

A presentation at the ongoing annual meeting of the European  Society of Medical Oncology (ESMO), in Madrid, Spain, has offered us data comparing abiraterone acetate + prednisone + ADT to docetaxel + ADT in the treatment of men with high-risk, metastatic, hormone-sensitive prostate cancer (mHSPC). … READ MORE …

Adding ADT to radiation therapy may carry increased cardiovascular risk

Some recent randomized clinical trials have shown that adding androgen deprivation therapy (ADT) to radiation therapy can improve outcomes in some circumstances. However, … READ MORE …

ADT and radiation for first-line treatment of node-positive (N1) prostate cancer

It’s now a relatively rare occurrence (about 12 percent of new patients) to be newly diagnosed with pelvic lymph node positive (N1) prostate cancer. Traditionally, this had been treated with ADT only because radiation therapy (RT) was thought to be of no benefit in extending survival. … READ MORE …

IADT, dutasteride, and the AVIAS trial — not the result some would want to hear

So the initial results of the AVIAS trial are not going to make a couple of our regular readers too happy — although at least a trial of the type they have been asking for has now been carried out. … READ MORE …

Two different “takes” from the results of the CHAARTED trial

In the October 15 issue of Oncology differing authors provide differing perspectives on the interpretation of the results of the CHAARTED trial reported by Sweeney et al. at the annual meeting of the American Society for Clinical Oncology earlier this year. … READ MORE …

Resistance training and quality of life among men on ADT

A newly published study has added to the mounting evidence that resistance training and related exercises are a valuable complement to medical care for men on androgen deprivation therapy (ADT). … READ MORE …

15-year survival and related data after first-line brachytherapy

Stone, Stock, and colleagues at the Icahn School of Medicine at Mount Sinai, New York, have been treating prostate cancer patients with brachytherapy since 1990 and (to whatever extent was possible) maintaining meticulous records throughout that time period. … READ MORE …

Sweeney et al. present results of CHAARTED trial at ASCO

So the data from the CHAARTED trial will be presented this afternoon at the ASCO meeting. This is the one really major and positive study result related to prostate cancer that we knew was coming at this meeting. … READ MORE …

Surprise: exercise is good for men on ADT!

According to a review article recently published in the Journal of Clinical Oncology, “Among patients … treated with androgen-deprivation therapy, appropriately prescribed exercise is safe and may ameliorate a range of treatment-induced adverse effects.” … READ MORE …

Early docetaxel chemotherapy + ADT extends survival of men with metastatic prostate cancer

According to a media release issued yesterday by the National Institutes of Health, the CHAARTED clinical trial has shown that men with hormone-sensitive, metastatic prostate cancer who received docetaxel chemotherapy at the start of standard androgen deprivation therapy (ADT) lived longer than patients who received ADT alone. … READ MORE …

10-year data from RTOG 9910 endorses 8 weeks of neoadjuvant ADT prior to radiation

According to a report on Practice Update last Monday, some interesting data were presented at a plenary session at the annual meeting of the American Society for Radiation Oncology (ASTRO) based on 10-year follow-up of men in the RTOG 9910 trial. … READ MORE …

New Phase III trial is testing ADT + bicalutamide vs. ADT + TAK-700

It has been brought to our attention that the Southwest Oncology Group (SWOG) has initiated a new, randomized, double-blind, multi-center, Phase III trial designed to compare androgen deprivation therapy (ADT) + bicalutamide (Casodex) to ADT + the investigational drug TAK-700 in men newly diagnosed with metastatic, hormone-sensitive prostate cancer. … READ MORE …

The impact of ADT on diabetics who are also diagnosed with prostate cancer

It has long been understood that treatment of prostate cancer with androgen deprivation therapy (ADT) can both increase the risk for diabetes among non-diabetic patients and can decrease sensitivity to insulin among men with diabetes. What has been missing, however, are good data about how ADT affects diabetes control among men with diabetes. … READ MORE …

Strength training and quality of life in Black prostate cancer patients on ADT

Black males have high rates of incidence and mortality associated with prostate cancer … significantly higher than Caucasians of similar ages. Thus, Black male patients are more likely to require androgen deprivation therapy (ADT) for prostate cancer (PCa), and suffer associated side effects (including loss of muscle mass, weakness, fatigue, and reduced quality of life [QoL]). … READ MORE …

Degree of loss of muscle mass among men on long-term ADT

Unsurprisingly, according to a new article in the Journal of Clinical Oncology, long-term androgen deprivation therapy (ADT) is closely associated with loss of lean muscle mass (known as sarcopenia) in men being treated for prostate cancer. However, this appears to be the first time anyone has shown there is an age-related factor that is relevant to the degree of loss of lean muscle. … READ MORE …